Immune Thrombocytopenic Purpura following CoronaVac vaccination: a case report

Authors

  • Giulia Eduarda Turra Aimi Unimed Nordeste. Caxias do Sul, RS, Brasil.
  • Guilherme Rasia Bosi Unimed Nordeste. Caxias do Sul, RS, Brasil. https://orcid.org/0000-0002-9750-9342
  • Larissa Beatriz Guerra Unimed Nordeste. Caxias do Sul, RS, Brasil.
  • Lessandra Michelin Unimed Nordeste. Caxias do Sul, RS, Brasil.

DOI:

https://doi.org/10.22491/2357-9730.121930

Keywords:

#covid19

Abstract

Immune thrombocytopenic purpura (ITP), an autoimmune disorder, has been documented as a result of SARS-CoV-2 infection and a vaccination side effect. The COVID-19 pandemic has led to the creation of CoronaVac vaccine and has been widely administered in Brazil.

 Patient, in the case, is an 82-years-old female who received the vaccine two days before an acute episode of gingivorrhagia and diffuse cutaneous petechiae. Other exams were made to look for other causes of secondary thrombocytopenia and all the results were normal.  The patient showed improvement on the platelet levels three day after the beginning of the treatment with high dosage methylprednisolone.

Knowing that other kinds of vaccine can generate ITP, the SARS-CoV-2 vaccine could be related to the symptoms.

Downloads

Download data is not yet available.

Published

2023-03-03

How to Cite

1.
Turra Aimi GE, Bosi GR, Guerra LB, Michelin L. Immune Thrombocytopenic Purpura following CoronaVac vaccination: a case report. Clin Biomed Res [Internet]. 2023 Mar. 3 [cited 2025 Aug. 11];42(4). Available from: https://seer.ufrgs.br/index.php/hcpa/article/view/121930

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.